Head to Head Analysis: Profusa (PFSA) vs. Its Rivals

Profusa (NASDAQ:PFSA) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare Profusa to related businesses based on the strength of its dividends, profitability, valuation, risk, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares Profusa and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,731.09%
Profusa Competitors	-303.57%	-175.14%	-22.20%

Institutional and Insider Ownership

9.8% of Profusa shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 15.0% of Profusa shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Profusa and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Profusa Competitors	4295	10588	18373	832	2.46

As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.09%. Given Profusa’s peers stronger consensus rating and higher probable upside, analysts clearly believe Profusa has less favorable growth aspects than its peers.

Valuation and Earnings

This table compares Profusa and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Profusa	$100,000.00	-$35.82 million	-0.00
Profusa Competitors	$1.87 billion	$137.20 million	5.88

Profusa’s peers have higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Profusa has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Profusa’s peers have a beta of 2.68, indicating that their average stock price is 168% more volatile than the S&P 500.

Summary

Profusa peers beat Profusa on 10 of the 13 factors compared.

Profusa Company Profile

Profusa, Inc. is a biotechnology and medical-device company focused on developing implantable biosensors designed to continuously monitor biochemical conditions inside the body. Its technology is intended to provide real-time health data without requiring repeated blood draws or external sampling. The company’s biosensors are designed to be placed under the skin and remain in the body while communicating measurements to an external reader or connected device. Profusa has developed platforms intended to monitor markers such as tissue oxygen levels, with potential applications in areas including peripheral artery disease, wound care, chronic disease management and clinical research.